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(absorbent). Three additional sub-states: without exacerbation, mild and severe 
exacerbation were considered. The effectiveness of treatment options and utilities 
for each health state were taken from the literature. Only direct health care costs 
were considered. Disease management and exacerbation costs were obtained from 
the literature. Drug costs were calculated based on ex-factory prices with mandatory 
7.5% rebate. All costs were updated to € 2012. A 3% annual discount rate on costs and 
health outcomes was applied. Incremental ratios in terms of cost per life-year gained 
(LYG) and cost per quality-adjusted life-year gained (QALY) of the most effective 
therapy versus the comparator were calculated. One-way sensitivity analyses were 
performed modifying the following parameters: time horizon (10 years, lifetime), 
discount rate (0%, 5%), drug costs (±10%, ±20%) and utilities (±10%). Probabilistic 
sensitivity analysis (PSA) was also performed. Results: At 5 years, glycopyrronium 
bromide accounted a total cost of € 2,225.18 compared to € 2,374.81 accounted for 
tiotropium bromide. Glycopyrronium bromide yielded higher health benefits (4,321 
LYG and 3,388 QALY) than tiotropium bromide (4,315 LYG and 3,377 QALY). In all one-
way sensitivity analyses performed and in 100% of PSA simulations (1,000 iterations), 
glycopyrronium bromide compared to tiotropium bromide remained as a dominant 
strategy. ConClusions: Glycopyrronium bromide therapy in COPD patients is asso-
ciated to less costs and higher health benefits than tiotropium in Spain.
PRS37
Inhaled CoRtICoSteRoIdS (ICS) In tReatment of modeRate and SeveRe 
aSthma In RuSSIan fedeRatIon – ComPaRatIve PhaRmaCoeConomIC 
Study
Krysanov I., Tyapkina M.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: We conducted this pharmacoeconomic study to compare mometa-
sone furoate (M/F), fluticasone propionate (F/P) and budesonide (BUD) in treatment 
of moderate and severe asthma. Methods: Initially we conducted indirect com-
parison of efficacy and safety of studied therapies through the review of clinical 
data publications. We used cost minimization and cost effectiveness analysis for 
the pharmacoeconomic research. In the study we considered the direct costs of the 
three ICS and additional costs of β 2-adregenic agonist (salbutamol). We made calcula-
tions of costs for the most common treatment regimens in Russia: M/F 400 µg 1 dose 
once a day and F/P 125 µg 2 doses twice a day; M/F 400 µg 1 dose twice a day and F/P 
250 µg 2 doses twice a day; M/F 200 µg, 400 µg 1 dose twice a day and BUD 200 µg 2 
doses twice a day. Results: The review of clinical data demonstrated that M/F has 
similar efficacy to F/P and superior efficacy to BUD. The three ICS have similar safety 
profile. Use of M/F presents 10105 RUR (316 USD) in direct annual per patient costs 
for the treatment of moderate asthma and 20210 RUR (632 USD) for severe asthma. 
Cost minimization analysis showed, that the considered treatment regimens of M/F 
are cost effective compared to F/P 125 µg and 250 µg. M/F will save the health care 
system 28 to 50 USD per patient annually, though these results are price sensitive. 
Cost effectiveness analysis demonstrated that M/F has favorable CER compared to 
BUD: for 1% of FEV1 increase M/F 200 µg is 12 USD, M/F 400 µg is 24 USD and BUD is 
32 USD. These results are insignificantly price sensitive. ConClusions: M/F is the 
most cost effective of the three ICS as demonstrated by the results of cost minimiza-
tion and cost effectiveness analyses.
PRS38
the CoSt-effeCtIveneSS of dRy PowdeR antIbIotICS foR the tReatment 
of PSeudomonaS aeRugInoSa In PatIentS wIth CyStIC fIbRoSIS
Tappenden P.1, Harnan S.1, Uttley L.1, Mildred M.1, Taylor C.J.2, Brownlee K.3, Walshaw M.4
1University of Sheffield, Sheffield, UK, 2Sheffield Children’s NHS Foundation Trust, Sheffield, 
UK, 3Leeds Children’s Hospital, Leeds General Infirmary, Leeds, UK, 4Liverpool Heart and Chest 
Hospital NHS Foundation Trust, Liverpool, UK
objeCtives: To evaluate the cost-effectiveness of colistimethate sodium dry 
powder for inhalation (DPI) and tobramycin DPI versus nebulised tobramycin for 
the treatment of Pseudomonas aeruginosalung infection in patients with cystic 
fibrosis. Methods: We developed a state transition model based on transitions 
between strata of lung function measured in terms of Forced Expiratory Volume in 
1 Second (FEV1) % predicted. Health states representing post-lung transplantation 
and dead are also modelled. The model was informed by systematic reviews of evi-
dence concerning potential relationships between intermediate and final outcomes. 
The model assumes that treatment impacts on FEV1which manifests as changes 
in health-related quality of life. No survival benefit is assumed due to the absence 
of robust evidence. Model parameters were informed by two RCTs and best avail-
able evidence from the literature. Resource costs associated with drug acquisition, 
management of exacerbations and nebuliser maintenance were drawn from refer-
ence sources and expert opinion. Additional analyses of Patient Access Scheme 
(PAS) price discounts offered by the manufacturers of both DPI products were also 
undertaken. Results: Colistimethate sodium DPI is expected to produce fewer 
QALYs than nebulised tobramycin. Based on its list price, nebulised tobramycin is 
expected to dominate colistimethate sodium DPI. When the PAS is incorporated, 
the ICER for colistimethate sodium DPI versus nebulised tobramycin is expected 
to be approximately £288,600 saved per QALY lost. Based on its list price, the ICER 
for tobramycin DPI versus nebulised tobramycin is expected to be approximately 
£124,000 per QALY gained. When the proposed PAS is included, tobramycin DPI is 
expected to dominate nebulised tobramycin. ConClusions: Under their list prices, 
neither DPI product is likely to represent good value for money given current UK 
cost-effectiveness thresholds. The price discounts significantly improve the eco-
nomic attractiveness of both products. The cost-effectiveness of the DPIs against 
other nebulised antibiotics remains unclear.
PRS39
emPIRICal theRaPy foR ReSPIRatoRy tRaCt InfeCtIonS In an eRa of 
InCReaSIng antImICRobIal ReSIStanCe: a deCISIon and CoSt analySIS
Babela R.
St. Elisabeth University, BRATISLAVA, Slovak Republic
simulate the progressive course of COPD and its impact on quality adjusted life years 
(QALYs) in moderate to severe patients. Effectiveness was based on initial FEV1 increase 
included by using patient level improvement in one or more disease severity stages 
(according to GOLD guidelines) and annualized risk for exacerbation as observed in a 
1-year head-to-head randomized controlled trial (GLOW2). Initial FEV1 increase during 
the first year was followed by a constant decline in FEV1 in subsequent cycles. Based on 
list prices, annual drug costs were 3’825 Swedish krona (SEK)/447 EUR for glycopyrronium 
and 5’040 SEK/589EUR for tiotropium. Direct and indirect maintenance and exacerbation 
costs as well as utilities were extracted from published literature. Primary outcomes were 
QALYs and societal costs over 3 years, discounting future costs and benefits at 3%. Both 
one way and probabilistic sensitivity analysis have been performed. Results: Over 3 
years, glycopyrronium was found to be dominant (i.e. less costly and more effective) com-
pared with tiotropium. Treatment with glycopyrronium resulted in a minor QALY gain of 
0.005 compared with tiotropium. Total costs per patient were estimated at 73’752SEK / 
8’630 EUR for glycopyrronium and 79’357 SEK /9’286 EUR for tiotropium, resulting 
in an average cost saving of 5’605SEK /656 EUR per patient after 3 years. Univariate 
sensitivity analyses showed that base-case results were robust and probabilistic sen-
sitivity analyses resulted in 99% of generated samples with glycopyrronium to be 
dominant. ConClusions: From a Swedish societal perspective, glycopyrronium was 
estimated to be cost-effective compared with tiotropium based on the progressive course 
of COPD and risk for exacerbation in moderate to severe patients as observed in the 
head-to-head study GLOW2.
PRS34
CoSt-effeCtIveneSS analySIS of CaRbaPenemS In tReatment 
noSoComIan PneumonIa In ukRaIne
Iakovlieva L.1, Bezditko N.1, Glumcher F.2, Dubrov F.2
1National University of Pharmacy, Kharkiv, Ukraine, 2O.O. Bogomolets National Medical 
University, Kyiv, Ukraine
objeCtives: To conduct a cost-effectiveness analysis of carbapenems use (imipenem, 
meropenem, and doripenem) in treatment nosocomial pneumonia. Methods: Cost-
effectiveness analysis based on decision-tree model was conducted from patient’s 
(out-of-pocket drugs costs) and state (drugs costs and hospitalization expenses) 
perspectives. The input data on therapy duration and drugs’ doses were retrieved 
from randomized controlled trials and clinical standards. The drugs doses were equal 
to: 2.0g /day from imipenem/cilastatin, 3.0g /day for meropenem, and 1.5g/day for 
doripenem. The model considered that in the case of drugs effectiveness the treat-
ment continued till successful outcome, and in a case of non-effective treatment, the 
second line therapy (vancomycin or colomycin depending on type of infection) was 
applied. The data on infections resistance and empirical effectiveness of antibiotics 
were retrieved from the largest microbiologic study conducted in Ukraine. Results: 
The lowest cost- effectiveness ratio correspond to the initial therapy with imipenem/
cilastatin (CER 910$/1158$ vs. 1280$/1648$ for meropenem and 1317$/1712$ for dorip-
enem from state and patient’s perspectives accordingly). ConClusions: Thus, 
empiric therapy with meropenem increases the costs of medical treatment by 29 %, 
with doripenem – by over 35 %. Sensitivity analysis of the results of calculations versus 
changes of level of MRSA-resistant and carbapenem-resistant strains demonstrated 
reliability of the received results.
PRS35
CoSt-effeCtIveneSS analySIS of PalIvIzumab aS a PRoPhylaxIS 
foR ReSPIRatoRy SynCytIal vIRuS (RSv) InfeCtIon In hIgh-RISk late 
PReteRm InfantS In the netheRlandS
Langenfeld M.K., Visser S.
AbbVie BV, Hoofddorp, The Netherlands
objeCtives: To determine the cost-effectiveness of palivizumab for the prevention 
of serious lower respiratory tract infection requiring hospitalization caused by RSV 
compared to no prophylaxis in high-risk infants born at 33-35 weeks of gestational 
age (wGA) according to the Dutch RISK model. Methods: A decision tree model was 
developed using data from published literature, palivizumab clinical trials, the Dutch 
RISK score model, official price/tariff lists and Dutch national population statistic. 
The comparator was no prophylaxis. The primary perspective of the study was that 
of the society in The Netherlands. Time horizon was lifetime. The cost valuation is 
based on the direct health care costs, direct nonmedical costs and indirect costs. 
Costs were assessed in 2012 Euros. The costs and utilities are discounted by 4% and 
1.5%, respectively, from the second year onwards, and no discounting is applied in 
the first year. Results: The base case results show that the use of palivizumab 
leads to an additional cost of € 4,116, whereas the use of palivizumab leads to a 
gain of 0.201 life years and 0.265 QALYs. Although the use of palivizumab increases 
the costs compared with no prophylaxis, palivizumab-treated patients experienced 
more QALYs and a gain in life years. Subsequently, palivizumab results in an ICER of 
€ 15,520 per QALY gained compared to no prophylaxis. The ICER in cost per LYG is € 
20,440. ConClusions: This analysis showed that palivizumab was cost-effective as 
a prophylaxis against RSV infection requiring hospitalisation in high-risk late prema-
ture infants compared to no prophylaxis. Extensive sensitivity analyses and explored 
scenarios underline the robustness of the demonstrated base case cost-effectiveness.
PRS36
CoSt-effeCtIveneSS analySIS of glyCoPyRRonIum bRomIde In the 
tReatment of ChRonIC obStRuCtIve PulmonaRy dISeaSe In SPaIn
Torres C.1, Betoret I.2, Sabater E.1, Figueras M.2, Casado M.A.1
1Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain, 2Novartis, Barcelona, Spain
objeCtives: To assess the cost-effectiveness and cost-utility of glycopyrronium 
bromide versus tiotropium bromide in Chronic Obstructive Pulmonary Disease 
(COPD) patients, from the Spanish National Health System perspective. Methods: 
A Markov model was developed to compare glycopyrronium bromide and tiotro-
pium therapies. Progression of a COPD patient cohort was simulated for a 5-year 
time horizon (3 months-cycle duration). The health states included were defined 
according to the severity of COPD: mild, moderate, severe, very severe and death 
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PRS42
eConomIC ImPaCt of a SmokIng CeSSatIon PRogRam In mexICo: 
enRollIng emPloyeeS and emPloyeRS
Huicochea-Bartelt J.L., Muciño-Ortega E., Hernandez-Reyes F.C.
Pfizer S.A. de C.V., Ciudad de México, Mexico
bACkgRound: Smoking costs at work affect both employers and employees. These 
costs are a result of a combined loss of productivity, time off work due to illness, 
smoking breaks and increasing insurance costs. objeCtives: This study aims to 
evaluate the economical impact of a 12 week smoking cessation program with 
varenicline from an employer perspective in a medium size Mexican-Corporate set-
ting. Methods: A decision tree was built in order to estimate the two endpoints of 
the program: resource used in terms of costs and productivity gains in labor hours, 
in a three year horizon. Smokers enrolling in the program were assumed to be the 
proportion of people who reported being very much indeed interested on quitting 
smoking in a 2005 UK survey (27%). A promotional cost of a 12 week combo-pack of 
varenicline was provided by the manufacturer. A literature review was performed 
in order to obtain smoking specific data of the country and response rates. Labor 
costs were retrieved from the Mexican National Institute of Statistics and Geography 
(INEGI). A base scenario of a medium sized company (250 employees) was assumed 
to show the potential benefits of the program. Results: Assuming a 250 employ-
ees company and a shared proportion of 50% of the costs of the program between 
employees and employers, companies would have to invest US$178 per employee 
only at the first year, and have potential savings of US$228 for each of them after 
3 years. At the same circumstances the net productivity gains per programme 
participant would be in an amount of 70.8 hours. ConClusions: This research 
showed that if mexican employers invest in a smoking cessation program, signifi-
cant productivity gains and savings could be reached in a 3 year horizon.
ReSPIRatoRy-Related dISoRdeRS – Patient-Reported outcomes & Patient 
Preference Studies
PRS43
the RelatIonShIP between tReatment SatISfaCtIon and adheRenCe In 
CoPd PatIentS In 5 CountRIeS
Vietri J.1, Isherwood G.2
1Kantar Health, Milan, Italy, 2Kantar Health, Epsom, Surrey, UK
objeCtives: To assess the relationship between treatment satisfaction and adherence 
in chronic obstructive pulmonary disease (COPD) in European patients, and whether the 
strength of this relationship varies according to country. Methods: Data were taken 
from the 5EU (France, Germany, Italy, Spain, and UK) 2011 National Health and Wellness 
Survey (NHWS), a cross-sectional survey representative of the total adult populations 
in each 5EU country. The current analysis included all respondents taking one or two 
treatments for COPD (including chronic bronchitis, COPD, and emphysema; n= 914). 
Satisfaction with medication was measured using a single item per treatment, and 
averaged for respondents taking two treatments. Adherence was measured using a sin-
gle 4-item Morisky Medication Adherence Scale (MMAS) for all COPD treatments used. 
Spearman correlations were used to assess the relationship when adherence was consid-
ered as an ordinal variable, and binary logistic regressions were used to assess the rela-
tionship between the two constructs when adherence was dichotomized. Regressions 
included age and gender as covariates. Results: Bivariate correlations demonstrated 
a modest relationship between satisfaction and adherence within COPD patients across 
the five countries rs = .133, p< 0.001). The strength of this relationship ranged from a low 
of rs = 0.05 in France (p = 0.60) to a high of rs= .37 in Spain (p< 0.001). A significant interac-
tion between country and satisfaction confirmed that the relationship varied by country. 
When the relationship was examined within each country, satisfaction was a signifi-
cant predictor of adherence only in Spain and the UK (both p< 0.05). ConClusions: 
Mean level of adherence to COPD treatments differed across European countries. Higher 
satisfaction was generally associated with greater adherence, but the strength of this 
relationship varied. Ensuring treatments are satisfactory to the patient may promote 
greater adherence, but the strength of the impact is likely to vary across populations.
PRS44
faCtoRS Related to adheRenCe afteR a multIfaCtoRIal InteRventIon 
to ImPRove It In PatIentS wIth ChRonIC obStRuCtIve PulmonaRy 
dISeaSe (CoPd). ICePoC Study
Leiva-Fernandez F.1, Leiva-Fernandez J.2, Prados-Torres D.1, García-Ruiz A.J.3, Barnestein-
Fonseca P.1
1Distrito Sanitario Málaga (SAS), Málaga, Spain, 2Area Sanitaria Málaga Este-Axarquia, Málaga, 
Spain, 3Malaga University, Malaga, Spain
objeCtives: To identify factors related to adherence after a multifactorial interven-
tion in patients with COPD. Methods: Design: Randomized Controlled Trial (ISRCTN 
15106246) Patients: 146 subjects randomly allocated (random blocks of 4 patients) in 
two groups (intervention group-IG, control group-CG). Intervention components: 1)
Motivational aspects: beliefs-behaviour about COPD (group and individual interviews); 
2) Cognitive aspects: information about illness; and 3) Skills: inhaling techniques train-
ing. Follow-up: 1 year, 5 visits/group. Primary Outcome: adherence (pill/doses count); 
Secondary Outcomes: functional status (spirometry), quality of life (Saint George 
Respiratory Questionnaire-SGRQ); Independent variables: intervention, age, sex, edu-
cational level, comorbidity, COPD severity stage (SEPAR guidelines), prescribed medi-
cation. Statistical analysis: Four partial logistic regression models, fixed- and random 
effects estimation, were carried out, a final model was built considering them. Statistical 
packages SPSS 15.0 and Stata 11.1. Results: Predominance of males (91.8%), mean 
age 69.08 years (CI95%,67.58-70.44); low cultural level (78.1%), 32.2% current smokers 
(62.84 pack-years [CI95%,55.34-70.34]), Body Mass Index 30.78 kg/m2 (CI95%,28.78-
32.78), 81.2% mild-moderate severity stage, predominance of obstructive respiratory 
pattern; FEV1 (mean)= 67.58% (CI95%,64.58-71.08), 0.87 exacerbations/year [CI95%, 0.68-
1.06]. Pharmacological treatment: inhaled-beta2-adrenergic (80.1%); inhaled-anticho-
linergic (77.4%); inhaled-corticosteroids (70.5%); mucolitycs (11.6%); xanthine (8.2%); 
oxygen therapy (4.8%); oral-corticosteroids (0.7%). Adherence was 41% (41.2CG/40.8IG). 
objeCtives: To analyze the costs of macrolides use compared to cephalosporines 
for treatment of Acute Bacterial Sinusitis (ABSs) in the era of increasing resist-
ance to Streptococcus pneumoniae. Methods: We used a decision analysis model 
(TreeAge Pro 2013) to perform a cost-minimization and sensitivity analysis to 
determine what level of macrolide resistance in a community would trigger cepha-
losporine use. Costs and clinical outcomes of ABSs were extracted from a system-
atic review of the literature and official local databases. Clinical response was 
derived from prospective clinical trials, investigations and from clinical experts 
experience, were we had ≤ 1 source. Results: We have found that the mean cost 
of empirical treatment with macrolides for ABSs was 79 EUR when community 
S. pneumoniae resistance was at 0%; 77 EUR at 10%; 82 EUR at 20% and 88 EUR at 
30%. Cephalosporines were found to be cost-minimizing when the prevalence of 
macrolide resistance to S. pneumoniae exceeded 15%. Sensitivity analysis variables 
that had a significant impact on our cost-minimization threshold included propor-
tion of macrolide resistance to S. pneumoniae, cost of antibiotics and probabilities 
of clinical cure with antibiotics. ConClusions: We believe we have performed 
the first cost-based model and sensitivity analysis to determine what level of 
macrolide resistance in the community could trigger a switch of empirical therapy 
for ABSs from macrolides to cephalosporines in Slovakia. Our investigation is 
to our knowledge also locally the first to employ decision analysis to explore 
the relationship between antimicrobial resistance and clinical decision making 
in ABSs. From a payer perspective, cephalosporines appears to be a reasonable 
alternative to macrolides for empirical treatment of ABSs, especially given the 
current prevalence of macrolides resistance among S. pneumoniae in community 
that reached 30% level, nationwide.
PRS40
eConomIC evaluatIon of mandIbulaR advanCement devICe to tReat 
obStRuCtIve SleeP aPnea
Giannopoulou A.1, Burgers L.T.1, van Bruggen M.P.B.2, de Vries N.3, Redekop W.K.1,  
Rijnsburger A.1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Philips Research Europe, 
Eindhoven, The Netherlands, 3St. Lucas Andreas Hospital, Amsterdam, The Netherlands
objeCtives: In the treatment of obstructive sleep apnea/hyoponea syndrome 
(OSAHS) moderate patients are primarily offered Continuous Positive Airway 
Pressure (CPAP). This study aims to assess the cost-effectiveness of mandibular 
advancement device (MAD), a commonly suggested alternative, as compared to 
CPAP for moderate OSAHS patients in The Netherlands. Methods: The prognosis 
of a hypothetical cohort of 50-year-old patients with moderate OSAHS was simu-
lated with a Markov model to estimate the costs and quality-adjusted life-years 
(QALYs) for both CPAP and MAD. A distinctive factor incorporated in the model 
was switch of therapy. All input parameters, including the risks of experiencing 
myocardial infarction, stroke and motor vehicle crashes (MVC) were based on lit-
erature and clinical expert opinion. Costs and effects were estimated over a 5-year 
time horizon using a health care provider perspective and were discounted at a 
rate of 4% and 1.5%, respectively. Robustness of the results was investigated with 
several sensitivity and scenario analyses. Results: Compared with CPAP, MAD 
is less expensive (€ 4,511 vs. € 5,302) and only slightly less effective (3.44 vs. 3.49 
QALYs) resulting in an incremental cost-effectiveness ratio (ICER) of € 15,393 saved 
per QALY lost. The most influential parameter was the cost of MAD device and its 
titration. Quality-of-life values, compliance rates, costs and the probabilities of 
switching treatment, cardiovascular events and MVC were varied in the scenario 
analyses. Under the majority of the scenarios MAD remained less cost-effective 
compared to CPAP. ConClusions: Over a 5-year time horizon, MAD therapy may 
be considered not cost-effective in the treatment of moderate OSAHS patients in 
The Netherlands. Further research on the impact of both treatments on long-term 
risks and improvement in the quality of life is required. Similarly, more long-term 
studies using a uniform compliance definition are needed to inform future cost-
effectiveness analyses.
PRS41
IntegRatIng the long-teRm health buRden of oRal CoRtICoSteRoIdS 
In the CoSt-effeCtIveneSS of omalIzumab
Faria R., McKenna C.
University of York, York, UK
objeCtives: Omalizumab offers an alternative to maintenance oral corticosteroids 
(OCS) in the treatment of severe persistent asthma. Despite widespread recognition 
of the adverse effects from OCS, there is little quantitative evidence on their health 
burden or costs. Failing to account for the adverse effects of OCS may underestimate 
the cost-effectiveness of innovative steroid-sparing medicines such as omalizumab. 
This study aims to explore the possibilities for integrating evidence on the burden of 
OCS in cost-effectiveness analysis using omalizumab as a case study. Methods: A 
model was developed to evaluate the long-term cost-effectiveness of omalizumab in 
patients requiring maintenance OCS. Costs were from a health service perspective 
and outcomes were measured as quality-adjusted life years (QALYs). The burden from 
maintenance use of OCS was quantified with population-based approach, with a deci-
sion model and with threshold analysis. Results: The incremental cost-effectiveness 
ratio (ICER) was £37,987 per QALY gained, which is above conventional thresholds used 
in the UK. Threshold analysis showed that the annual health losses from maintenance 
use of oral corticosteroids would need to be 0.12 QALYs per year. This is double the 
quantifiable health losses with the population-based approach and with the decision 
model and 10% of the health gains achieved with omalizumab. ConClusions: The 
burden from maintenance OCS can be integrated in cost-effectiveness analysis but 
the extent to which these estimates account for their full impact on health depends 
on the approach used and underlying assumptions. The challenges arise from sparse 
randomised evidence, time lag in the adverse effects and unclear relationship between 
risk and long-term steroid load. These are empirical questions which can be answered 
with further research. Such research would be valuable not only for decision making in 
severe asthma but also for other conditions treated with maintenance OCS.
